Amgen and Novartis swap Alzheimer's, migraine candidates
Novartis AG and Amgen Inc. teamed up in a CNS deal: Novartis partnered its lead BACE inhibitor for Alzheimer's with Amgen, which granted Novartis rights to its migraine program.
- Large Molecule
- Includes Contract
- Includes Royalty or Profit Split Information
- Product or Technology Swap
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.